RESUMEN
Three trials investigated the pharmacokinetics (PK) of recombinant factor XIII (rFXIII) A-subunit. To compare the PK characteristics of rFXIII among trials and different age groups of patients. Dosing with rFXIII 35 IU kg(-1) every 4th week. Blood samples for PK assessments were collected regularly throughout the dosing interval from a total of 68 individual patients with FXIII congenital deficiency. The mean PK parameters were similar across the three age groups, and for the three trials, as well as constant over time based on results from patients participating in both mentor 1 and mentor 2 trials. The geometric mean half-life ranged from 11.6 to 15.0 days, and the trough FXIII activity levels ranged from 0.15 to 0.21 IU mL(-1) . The population PK model identified body weight as a statistically significant covariate influencing clearance (CL) and volume of distribution (Vd ), with a similar increase in both parameters with increased body weight. The half-life was not affected by body weight. Gender (females vs. males) and age category (paediatric vs. adult) did not affect CL. The PK profile of rFXIII, after dosing with 35 IU kg(-1) of rFXIII, was independent of age and comparable between trials and FXIII trough activity levels were constant. Despite rather large individual variation in the maximal FXIII activity levels, all individual mean trough activity levels were above 0.1 IU mL(-1) during the entire duration of the trials. The results support that monthly dosing with 35 IU kg(-1) of rFXIII to patients with FXIII A-subunit deficiency, regardless of age, is adequate for prophylaxis.
Asunto(s)
Deficiencia del Factor XIII/tratamiento farmacológico , Deficiencia del Factor XIII/genética , Factor XIII/genética , Factor XIIIa/farmacocinética , Factor XIIIa/uso terapéutico , Subunidades de Proteína/genética , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/uso terapéutico , Adolescente , Adulto , Niño , Preescolar , Factor XIII/química , Femenino , Humanos , Lactante , Masculino , Subunidades de Proteína/deficiencia , Factores de Riesgo , Resultado del Tratamiento , Adulto JovenRESUMEN
In focal cerebral ischemia the plasminogen-plasmin system plays a role in the fibrinolysis of vessel-occluding clots and also in the proteolysis of extracellular matrix components, which potentially contributes to brain edema and bleeding complications. The authors investigated the plasminogen activation after middle cerebral artery occlusion with and without reperfusion (reperfusion intervals 9 and 24 hours) in rats by histologic zymography and compared areas of increased plasminogen activation to areas of structural injury, which were detected immunohistochemically. After 3 hours of ischemia, increased plasminogen activation was observed in the ischemic hemisphere. The affected area measured 5.2%+/-8.5% and 19.4%+/-30.1% of the total basal ganglia and cortex area, respectively. Reperfusion for 9 hours after 3 hours of ischemia led to a significant expansion of plasminogen activation in the basal ganglia (68.8%+/-42.2%, P < 0.05) but not in the cortex (43.0%+/-34.6%, P = 0.394). In the basal ganglia, areas of increased plasminogen activation were related to areas of structural injury (r = 0.873, P < 0.001). No such correlation was found in the cortex (r = 0.299, P = 0.228). In this study, increased plasminogen activation was demonstrated early in focal cerebral ischemia. This activation may promote early secondary edema formation and also secondary hemorrhage after ischemic stroke.
Asunto(s)
Infarto de la Arteria Cerebral Media/metabolismo , Ataque Isquémico Transitorio/metabolismo , Plasminógeno/metabolismo , Daño por Reperfusión/metabolismo , Animales , Arteriopatías Oclusivas/metabolismo , Ganglios Basales/irrigación sanguínea , Ganglios Basales/química , Ganglios Basales/enzimología , Edema Encefálico/metabolismo , Corteza Cerebral/irrigación sanguínea , Corteza Cerebral/química , Corteza Cerebral/enzimología , Hemorragia Cerebral/metabolismo , Modelos Animales de Enfermedad , Activación Enzimática , Fibrinolisina/metabolismo , Masculino , Proteínas Asociadas a Microtúbulos/análisis , Proteínas Asociadas a Microtúbulos/metabolismo , Ratas , Ratas WistarRESUMEN
The morphology of neurosecretory cells that project from the suboesophageal ganglion into the retrocerebral complex via the Nervus corporis allati II (NCA II) was studied in the migratory locust, Locusta migratoria, using backfilling techniques and intracellular staining. There are two populations of cells located ventrally in the ganglion: an anterior group of four larger cells, and a posterior group of up to 22 smaller cells. Apart from cell body size and position, members of both cell groups have almost all features in common. They show long-lasting soma spikes with large amplitudes typical for arthropod neurosecretory cells. Their dendritic arborisations are found in the same regions of the neuropile. Both types project into the corpora cardiaca and an additional putative neurohaemal region associated with posterior pharyngeal dilator muscles. The axons of the cells bypass the corpora allata, but frequently form putative release sites on the surface of nerve branches in the vicinity of these glands. Finally, using double-labelling techniques, both anterior and posterior cells are shown to be identical with immunoreactive suboesophageal ganglion cells detected in previous studies using antisera directed against either bovine pancreatic polypeptide (BPP) or locustamyotropin II (Lom-MT-II).
Asunto(s)
Ganglios/citología , Saltamontes/anatomía & histología , Sistemas Neurosecretores/citología , Animales , Femenino , Inmunohistoquímica , Masculino , Neuronas/citología , Coloración y EtiquetadoRESUMEN
Calpains are intracellular proteinases whose proteolytic activity is directed mainly against the cytoskeleton and regulatory proteins. We studied the presence of calpain by immunohistochemistry in a rat model of reversible focal cerebral ischemia (3 h) at various times of reperfusion. The numbers of calpain-positive cells on the ischemic side were compared with the non-ischemic side. In controls only 2 +/- 1% cells were positive, whereas the cortex of the ischemic vs the non-ischemic side showed 88 +/- 3% vs 13 +/- 4% calpain-positive cells (p < 0.001), and the basal ganglia 47 +/- 3% vs 13 +/- 4% (p < 0.01) after 3 h ischemia and 24 h reperfusion. This is the first demonstration of elevated intracellular levels of calpains in areas of cerebral ischemia. Longer reperfusion resulted in an increase in calpain positivity.
Asunto(s)
Isquemia Encefálica/metabolismo , Calpaína/metabolismo , Líquido Intracelular/metabolismo , Animales , Ganglios Basales/metabolismo , Ganglios Basales/patología , Isquemia Encefálica/patología , Corteza Cerebral/metabolismo , Corteza Cerebral/patología , Inmunohistoquímica , Masculino , Neuroglía/metabolismo , Neuronas/metabolismo , Ratas , Valores de Referencia , Daño por Reperfusión/metabolismo , Daño por Reperfusión/patología , Factores de TiempoRESUMEN
BACKGROUND: Previous experimental work using in situ zymography has shown very early increased plasminogen activation in ischemic regions after 3 h of ischemia with and without reperfusion. The objective of the present study was to evaluate the time course and extent of plasminogen activation in long-term permanent focal cerebral ischemia. MATERIAL AND METHODS: The middle cerebral artery in male Fisher rats was irreversibly occluded by electrocoagulation. Duration of ischemia was 48, 72, and 168 h. Occlusion was controlled in vivo by MRI at day 2. Plasminogen activation was detected by in situ zymography of 10 microm cryosections with an overlay containing plasminogen and the plasmin substrate caseine. Areas of plasminogen activation were compared to structural lesions (immunohistochemical loss of microtubule-associated protein 2; MAP 2). RESULTS: Compared to controls, increased plasminogen activation was observed in the basal ganglia and the cortex of the ischemic hemisphere after 48, 72, and 168 h (affected area of basal ganglia: 44.5+/-21.9, 70.1+/-2.3 and 66.6+/-2.8%, respectively; affected area of cortex: 63.4+/-9.8, 67.7+/-0.7 and 64.0+/-3.7%, respectively). The duration of ischemia had no significant influence on the extent of plasminogen activation. Areas of increased plasminogen activation significantly overlapped with and exceeded areas of MAP 2 loss (P<0.005). DISCUSSION: Permanent focal cerebral ischemia leads to increased plasminogen activation in ischemic regions. This plasminogen activation remains elevated at persistent levels over days. It may contribute to extracellular matrix (ECM) disruption, secondary hemorrhage, and brain edema in subacute stages of ischemic stroke.